Loading...
•
Dec 31, 2021
Surmodics Q1 2022 Earnings Report
Surmodics reported a revenue increase of 3% year-over-year, with a GAAP EPS of $(0.20) and a non-GAAP EPS of $(0.13).
Key Takeaways
Surmodics, Inc. announced its first quarter fiscal 2022 results, showing a 3% increase in revenue compared to the prior-year period. The company's GAAP EPS was $(0.20), while non-GAAP EPS was $(0.13). Surmodics also saw the first commercial sale of its Pounce™ Arterial Thrombo-embolectomy System.
Revenue increased by 3% year-over-year, reaching $23.0 million.
GAAP EPS was $(0.20), and non-GAAP EPS was $(0.13).
First commercial sale of the Pounce™ Arterial Thrombo-embolectomy System occurred.
Progress was made on the SurVeil™ drug-coated balloon PMA submission.
Surmodics
Surmodics
Surmodics Revenue by Segment
Revenue by Segment
Medical Device Revenue
CapyFin.comIn Vitro Diagnostics Revenue
CapyFin.com Forward Guidance
Surmodics expects fiscal year 2022 revenue to range from $97 million to $101 million. The Company expects fiscal 2022 diluted GAAP EPS to range from a loss per share of $(2.05) to $(1.55), which reflects increased investments to accelerate the Company’s strategy. Non-GAAP diluted EPS for fiscal 2022 is expected to range from a loss per share of $(1.75) to $(1.25).
Revenue & Expenses
Visualization of income flow from segment revenue to net income